Enalapril

• Hypertension in adults and children
• Heart failure mortality reduction
• Asymptomatic left ventricular dysfunction
• Diabetic nephropathy protection
• Cardiovascular risk reduction

Enalapril is an angiotensin-converting enzyme (ACE) inhibitor that has been a cornerstone of cardiovascular medicine for decades. By blocking the conversion of angiotensin I to angiotensin II, it provides effective treatment for hypertension, heart failure, and asymptomatic left ventricular dysfunction, with proven benefits for reducing cardiovascular morbidity and mortality.

Mechanism of Action

Enalapril is a prodrug that is hydrolyzed in the liver to its active form, enalaprilat. Enalaprilat inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This results in decreased aldosterone secretion, reduced sodium and water retention, and vasodilation. Additionally, ACE inhibition decreases the breakdown of bradykinin, a vasodilator peptide, which contributes to the blood pressure-lowering effect but may also be responsible for the characteristic dry cough that occurs in some patients.

The neurohormonal modulation provided by ACE inhibitors extends beyond blood pressure control. In heart failure, enalapril reduces preload and afterload, decreases ventricular remodeling, and provides long-term cardiovascular protection that translates to improved survival and reduced hospitalizations.

Available Formulations

Enalapril maleate is available as oral tablets in 2.5 mg, 5 mg, 10 mg, and 20 mg strengths. Enalaprilat, the active metabolite, is available as an injectable solution (1.25 mg/mL) for intravenous use when oral administration is not feasible. A combination product with hydrochlorothiazide (Vaseretic) is available for patients requiring dual therapy.

FDA-Approved Indications

Enalapril is FDA-approved for hypertension in adults and pediatric patients one month of age and older, symptomatic heart failure (to reduce mortality and hospitalizations), and asymptomatic left ventricular dysfunction with ejection fraction 35% or less (to decrease rate of development of overt heart failure and reduce hospitalization for heart failure). These broad indications reflect the extensive clinical trial evidence supporting the cardiovascular benefits of ACE inhibition.

Dosing Guidelines

For hypertension, the typical starting dose is 5 mg once daily, with a usual dose range of 10-40 mg daily in one or two divided doses. For heart failure, start with 2.5 mg once or twice daily, titrating gradually to target doses of 10-20 mg twice daily as tolerated. Lower starting doses (2.5 mg) are recommended for patients with renal impairment, those on diuretics, or those at risk for hypotension. Monitor blood pressure, renal function, and potassium levels, especially during dose initiation and titration.

Clinical Trial Evidence

Enalapril has been studied extensively in landmark clinical trials that established the role of ACE inhibitors in cardiovascular medicine. The CONSENSUS and SOLVD trials demonstrated mortality reduction in heart failure. The SOLVD Prevention trial showed benefits in asymptomatic LV dysfunction. These trials, along with extensive post-marketing experience, have made enalapril one of the most well-characterized cardiovascular medications.

Important Safety Considerations

Enalapril carries a boxed warning for fetal toxicity; it should be discontinued immediately when pregnancy is detected due to risks of fetal injury and death. Angioedema can occur, particularly affecting the face, lips, tongue, and larynx, and may be life-threatening; it is more common in African American patients. Hyperkalemia may develop, especially in patients with renal impairment or those taking potassium supplements or potassium-sparing diuretics. Hypotension may occur, particularly with first doses in patients who are volume-depleted.

Drug Interactions

NSAIDs can reduce the antihypertensive effect and increase the risk of renal impairment. Potassium supplements and potassium-sparing diuretics increase the risk of hyperkalemia. Lithium levels may increase; monitor closely. Dual blockade of the renin-angiotensin system with ARBs or aliskiren is generally not recommended due to increased risks of hypotension, hyperkalemia, and renal impairment. Diuretics may enhance hypotensive effects.

The First Two Weeks: Labs, Symptoms and Expectations

The information that matters most in the first weeks on an ACE inhibitor comes from a blood test rather than from how the patient feels. Creatinine and potassium are rechecked within the first one to two weeks and again after each dose increase, because the drug lowers pressure inside the glomerulus and a modest rise in creatinine is expected physiology rather than injury. A small increase that then plateaus is not a reason to stop. A large or continuing rise prompts a search for volume depletion, an NSAID that has quietly been added, or narrowing of a renal artery. Potassium rises for the same neurohormonal reason and is the other number watched, particularly alongside a potassium-sparing diuretic, a potassium supplement, or spironolactone.

Patients should be told what to expect. Light-headedness on standing is commonest in the first days, especially in someone already taking a diuretic, and is managed by rising slowly and by taking the first dose at bedtime rather than by abandoning the drug. In hypertension (high blood pressure), the full effect of a given dose builds over several weeks, so the pressure is not rechecked two days later and judged a failure. In congestive heart failure the goal is different again: the dose is increased toward the target used in the trials because the survival benefit tracks the dose, and patients often feel no better at each step, which is worth saying in advance so that the titration is not abandoned halfway. Home readings taken correctly are more useful than office readings for judging the effect, and our article on home blood pressure monitoring the right way describes the technique.

Cough, Angioedema and the Move to an ARB

A dry, tickling cough is the reason most patients stop an ACE inhibitor. It is not dose-related, it can begin weeks or months after starting, and it does not respond to cough suppressants; the only reliable test is withdrawal, after which it usually settles within a few weeks. Because it is mediated by bradykinin rather than by angiotensin blockade, switching to an angiotensin receptor blocker such as losartan or valsartan preserves the cardiovascular and kidney benefit while resolving the cough in the large majority of patients, and that switch is routine rather than a concession.

Angioedema is different in kind. Swelling of the lips, tongue, face, or throat is an emergency, can occur after years of uneventful use, and means ACE inhibitors are not used again; a documented allergy entry in the chart is worth more than the patient's recollection years later. An angiotensin receptor blocker is usually tolerated afterward, but it is introduced deliberately and with the history discussed, not substituted casually at a pharmacy counter. Within the ACE inhibitor class itself, moving from enalapril to lisinopril or ramipril will not resolve either cough or angioedema, since the mechanism is shared; the real reasons to switch inside the class are dosing frequency, cost, and the particular trial evidence behind an individual agent. The MedlinePlus enalapril monograph covers what patients should report, and the NHLBI overview of heart failure treatment explains why these drugs are titrated toward a target dose rather than left at a starting dose. Our cardiovascular team manages the titration when several agents are being adjusted at once.

Special Populations

Dose reduction is required in renal impairment based on creatinine clearance. Use with caution in patients with bilateral renal artery stenosis or stenosis in a solitary kidney due to risk of acute renal failure. Enalapril is contraindicated during pregnancy. Safety and dosing have been established in pediatric patients one month of age and older for hypertension. Elderly patients may require lower starting doses due to age-related decreases in renal function.

Learn more at MedlinePlus